Abstract

Phosphate toxicity is a major threat to cardiovascular health in chronic kidney disease. It is associated with oxidative stress, inflammation and the accumulation of calcium phosphate commonly known as calcification in soft tissues leading to functional disorders of blood vessels. An improved calcification propensity test for the assessment of phosphate toxicity was developed, which measures the velocity of calcium phosphate mineralization from colloidal precursors in vitro. This so called T50 test measures the transformation from a primary into a secondary form of nanosized colloidal plasma protein-calcium phosphate particles known as calciprotein particles. The T50 test in its previous form required a temperature controlled nephelometer and several hours of continuous measurement, which precluded rapid bed side testing. We miniaturized the test using microfluidic polymer chips produced by ultrasonic hot embossing. A cartridge holder contained a laser diode for illumination, light dependent resistor for detection and a Peltier element for thermo control. Increasing the assay temperature from 37°C to 75°C reduced the T50 test time 36-fold from 381 ± 10 min at 37°C to 10.5 ± 0.3 min at 75°C. Incorporating sputtered micro mirrors into the chip design increased the effective light path length, and improved signal-to-noise ratio 9-fold. The speed and reproducibility of the T50 chip-based assay run at 75°C suggest that it may be suitable for rapid measurements, preferably in-line in a dialyser or in a portable microfluidic analytic device with the chip inserted as a disposable cartridge.

Highlights

  • IntroductionIzkf.rwth-aachen.de/index.php/en/izkf-aachen) and by the German Research Foundation

  • Chronic Kidney Disease (CKD) according to KDIGO (Kidney Disease: Improving Global Outcomes) guidelines requires that a measured glomerular filtration rate abnormality or evidence of kidney damage, or both, be present for a minimum of three months [1]

  • We developed a functional test measuring the overall calcification propensity in blood serum or plasma [19]

Read more

Summary

Introduction

Izkf.rwth-aachen.de/index.php/en/izkf-aachen) and by the German Research Foundation The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. AP and WJD are cofounders and share holders of Calciscon AG, a start-up company based at Nidau, Switzerland. AP is an employee of Calciscon AG, who provided support in the form of salaries for author AP, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call